Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 10/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21386619 | 0.85 | FGFR4 (0.37) | FGFR4FGFR1FGFR2FGFR3ALDH1A1 | |
| SCHEMBL21756586 | 0.84 | FGFR4 (0.38) | FGFR4PKMFGFR1FGFR2FGFR3 | |
| SCHEMBL21756616 | 0.84 | JAK2 (0.38) | FGFR4PKMMAPTKMT2AMEN1 | |
| SCHEMBL21756545 | 0.83 | FGFR4 (0.38) | FGFR4PKMFGFR1FGFR2FGFR3 | |
| SCHEMBL21756507 | 0.80 | FGFR1 (0.57) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL21386670 | 0.76 | FGFR4 (0.47) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL21756596 | 0.74 | CYP19A1 (0.41) | FGFR4PKMMAPTKMT2AMEN1 | |
| SCHEMBL22451317 | 0.74 | FGFR4 (0.34) | FGFR4FGFR1ALDH1A1 | |
| SCHEMBL20331444 | 0.73 | FGFR1 (0.38) | FGFR4FGFR1FGFR2FGFR3KMT2A | |
| SCHEMBL21756541 | 0.72 | FGFR4 (0.40) | FGFR4FGFR1FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008292-B2 | FGFR4 inhibitor and preparation method and use thereof | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2021-05-18 | — | — | US | disclosed |
| US-20210087181-A1 | SALT FORM AND CRYSTAL FORM OF COMPOUND AS FGFR4 INHIBITOR AND PREPARATION METHOD THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2021-03-25 | — | — | US | disclosed |
| US-20200062716-A1 | FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087181-A1 | SALT FORM AND CRYSTAL FORM OF COMPOUND AS FGFR4 INHIBITOR AND PREPARATION METHOD THEREOF | FGFR4, FGFR1, FGFR3 | FGFR4 1/4885PKM 4051/4885FGFR1 2/4885 |
| US-11008292-B2 | FGFR4 inhibitor and preparation method and use thereof | FGFR4, FGFR1, FGFR2 | FGFR4 1/4885PKM 2237/4885FGFR1 2/4885 |
| US-20200062716-A1 | FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | FGFR4, FGFR1, FGFR2 | FGFR4 1/4885PKM 2237/4885FGFR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.